



ASX/MEDIA RELEASE

27 March 2018

Update on Scheme of Arrangement – FIRB Approval

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) (**Sirtex**) today announces the Australian Foreign Investment Review Board (**FIRB**) has decided that the Commonwealth of Australia has no objection to Varian Medical Systems, Inc. (**Varian**) either directly or through one or more interposed wholly-owned subsidiaries acquiring up to 100% of Sirtex.

Receipt of this clearance in respect of the Scheme was a key condition to implementation of the Scheme.

– ENDS –

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.

Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations &
Corporate Development
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**
Visit us on LinkedIn: **Sirtex Medical Limited**